Coffee, ADORA2A, and CYP1A2: The caffeine connection in Parkinson's disease

European Journal of Neurology

Volumn 18, Issue 5, 2011, Pages 756-765

  Popat, R A ^a   Van Den Eeden, S K ^b   Tanner, C M ^c   Kamel, F ^d   Umbach, D M ^d   Marder, K ^e,f   Mayeux, R ^e,f   Ritz, B ^g   Ross, G W ^h,i   Petrovitch, H ^h,i   Topol, B ^a   Mcguire, V ^a   Costello, S ^j   Manthripragada, A D ^g   Southwick, A ^a   Myers, R M ^a,k   Nelson, L M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DIVISION OF RESEARCH   (United States)

^c PARKINSON S INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e Columbia University ^*  (United States)

^f Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY   (United States)

more..

Author keywords

Adenosine receptor A2A; Caffeine; Case control; CYP1A2; Epidemiology; Parkinson's disease; Polymorphisms

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2 RECEPTOR; CAFFEINE; CYTOCHROME P450 1A2;

ADULT; ARTICLE; COFFEE; COMPARATIVE STUDY; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRON; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; TELECONSULTATION;

AGED; CAFFEINE; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHOSPHODIESTERASE INHIBITORS; RECEPTOR, ADENOSINE A2A;

EID: 79954775770     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03353.x     Document Type: Article

References (28)

1. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
2. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143.
3. Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002; 322: 13-16.
4. Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006; 248: 9-15.
5. Fink JS, Kalda A, Ryu H, et al. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J Neurochem 2004; 88: 538-544.
6. Butler MA, Iwasaki M, Guengerich FP, Kadlubar F. Human cytochrome P450A (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci 1989; 86: 7696-7700.
7. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-77.
8. Facheris MF, Schneider NK, Lesnick TG, et al. Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord 2008; 23: 2033-2040.
9. Tan EK, Lu ZY, Fook-Chong SM, et al. Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 634-636.
10. Tan EK, Chua E, Fook-Chong SM, et al. Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenet Genomics 2007; 17: 1001-1005.
11. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022.
12. Kang GA, Bronstein JM, Masterman DL, et al. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005; 20: 1133-1142.
13. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995; 142: 820-827.
14. Marder K, Logroscino G, Alfaro B, et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998; 50: 279-281.
15. Alavanja MC, Sandler DP, McMaster SB, et al. The agricultural health study. Environ Health Perspect 1996; 104: 362-369.
16. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with risk of Parkinson disease. JAMA 2000; 283: 2674-2679.
17. Langston JW, Widner H, Goetz D, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
18. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study [published erratum In Neurology 1992;42:1436]. Neurology 1992; 42: 1142-1146.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, 1989.
20. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res 1998; 8: 195-202.
21. SAS System Under Microsoft Windows, Release 9.1 (TS2MO). Cary, NC: SAS Institute, Inc., 2006.
22. Troendle JF. Multiple comparisons between two groups on multiple Bernoulli outcomes while accounting for covariates. Stat Med 2005; 24: 3581-3591.
23. Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003; 28: 1694-1702.
24. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C to A polymorphism in intron 1 of the cytochrome P450 1A2 (CYP1A2) gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
25. Han X-M, Ou-Yang D-S, Lu P-X, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734 polymorphisms of human CYP1A2. Pharmacogenetics 2001; 11: 429-435.
26. Kim SH, Kim YK, Park HW, et al. Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respir Med 2009; 103: 356-363.
27. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295: 1135-1141.
28. Xu K, Xu Y-H, Chen J-F, Schwarzschild MA. Neuroprotection by metabolites of caffeine may prolong its neuroprotective effect in the MPTP model of PD. Soc Neurosci 2002: A487.5 Abstract.